Shopping Cart
Remove All
Your shopping cart is currently empty
Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $35 | In Stock | In Stock | |
| 50 mg | $56 | In Stock | In Stock | |
| 100 mg | $93 | In Stock | In Stock | |
| 500 mg | $228 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
| Description | Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain. |
| In vivo | Pivagabine (CXB 722) (200 mg/kg; i.p.; administered twice daily for 4 days and 1 hour before euthanasia on the 5th day) prevents foot-shock stress-induced changes in CRF concentration in both brain regions[2]. |
| Animal Research | Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions, reduced by 52% the CRF concentration in the hypothalamus but had no effect on that in the cerebral cortex[2]. |
| Synonyms | CXB-722 |
| Molecular Weight | 187.24 |
| Formula | C9H17NO3 |
| Cas No. | 69542-93-4 |
| Smiles | CC(C)(C)C(=O)NCCCC(O)=O |
| Relative Density. | 1.053 g/cm3 (Predicted) |
| Color | White |
| Appearance | solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (240.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.68 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.